Company Overview
Snapshot
Founded in April 2022 by Roei Zerahia and Omer Zerahia, MSICS Pharma operates with 11–50 employees. The company has raised $3.7 million across three funding rounds.
Business overview
MSICS Pharma is an Israeli Health Tech & Life Sciences company focused on the pharmaceutical production of naturally-sourced Psilocybin. The company has established a GMP production facility and is navigating a unique approval process, leveraging its experience with Cannabis. MSICS Pharma's core product, MSX-6, is poised for clinical trials in hospitals to treat conditions such as OCD, Anorexia, PTSD, and depression, targeting a multi-billion dollar market. The company aims to approve its products as prescribed medicine, starting in Israel as a beta-site and expanding globally to address unmet medical needs in the pharmaceuticals sector.
Strategic signal
In May 2026, MSICS Pharma announced it is advancing clinical trials for PTSD, depression, and OCD, signaling a critical step towards validating its naturally-sourced psilocybin products for mental health treatment. This development indicates the company's progress in bringing its pharmaceutical solutions to market and highlights its potential to address significant unmet medical needs in a rapidly evolving therapeutic landscape.
Log in to access full profile ›Company Intelligence Q&A
- What is MSICS Pharma's primary focus?
- MSICS Pharma is focused on the GMP production of naturally-sourced Psilocybin for pharmaceutical use, aiming to develop prescribed medicines for mental health conditions.
- When was MSICS Pharma founded and by whom?
- MSICS Pharma was founded in April 2022 by co-founders Roei Zerahia and Omer Zerahia.
- What conditions is MSICS Pharma targeting with its clinical trials?
- MSICS Pharma is preparing for clinical trials to treat conditions including OCD, Anorexia, PTSD, and depression.
- What is the total capital raised by MSICS Pharma?
- MSICS Pharma has raised a total of $3.7 million across three funding rounds.